Immatics Biotechnologies Gmbh Stock Shares Owned By Institutions
IMTXW Stock | USD 0.40 0.06 13.04% |
immatics biotechnologies GmbH fundamentals help investors to digest information that contributes to Immatics Biotechnologies' financial success or failures. It also enables traders to predict the movement of Immatics Stock. The fundamental analysis module provides a way to measure Immatics Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immatics Biotechnologies stock.
Immatics | Shares Owned By Institutions |
immatics biotechnologies GmbH Company Shares Owned By Institutions Analysis
Immatics Biotechnologies' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Immatics Shares Owned By Institutions Driver Correlations
Understanding the fundamental principles of building solid financial models for Immatics Biotechnologies is extremely important. It helps to project a fair market value of Immatics Stock properly, considering its historical fundamentals such as Shares Owned By Institutions. Since Immatics Biotechnologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immatics Biotechnologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immatics Biotechnologies' interrelated accounts and indicators.
Click cells to compare fundamentals
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Competition |
Based on the latest financial disclosure, 0.0% of immatics biotechnologies GmbH are shares owned by institutions. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Immatics Biotechnologies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immatics Biotechnologies from analyzing Immatics Biotechnologies' financial statements. These drivers represent accounts that assess Immatics Biotechnologies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immatics Biotechnologies' important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 583.4M | 423.8M | 743.6M | 546.8M | 767.3M | 480.3M | |
Enterprise Value | 483.3M | 222.4M | 620.4M | 412.8M | 564.3M | 373.5M |
Immatics Fundamentals
Return On Equity | -0.24 | ||||
Return On Asset | -0.12 | ||||
Profit Margin | (1.04) % | ||||
Operating Margin | (1.42) % | ||||
Number Of Shares Shorted | 736 | ||||
Revenue | 54 M | ||||
EBITDA | (88.93 M) | ||||
Net Income | (96.99 M) | ||||
Total Debt | 15.4 M | ||||
Book Value Per Share | 2.66 X | ||||
Cash Flow From Operations | 18.23 M | ||||
Number Of Employees | 542 | ||||
Beta | 0.78 | ||||
Market Capitalization | 673 M | ||||
Total Asset | 509.96 M | ||||
Retained Earnings | (597.29 M) | ||||
Working Capital | 292.82 M | ||||
Net Asset | 509.96 M |
About Immatics Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze immatics biotechnologies GmbH's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immatics Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of immatics biotechnologies GmbH based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.